Compare CCNE & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCNE | GYRE |
|---|---|---|
| Founded | 1865 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 736.3M | 755.7M |
| IPO Year | N/A | N/A |
| Metric | CCNE | GYRE |
|---|---|---|
| Price | $26.88 | $7.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $29.00 | $17.00 |
| AVG Volume (30 Days) | ★ 101.9K | 52.7K |
| Earning Date | 10-30-2025 | 11-07-2025 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.91 | 0.04 |
| Revenue | ★ $227,923,000.00 | $107,265,000.00 |
| Revenue This Year | $13.84 | $11.59 |
| Revenue Next Year | $27.68 | $26.31 |
| P/E Ratio | ★ $14.11 | $201.07 |
| Revenue Growth | ★ 5.27 | 2.13 |
| 52 Week Low | $19.32 | $6.11 |
| 52 Week High | $28.30 | $14.42 |
| Indicator | CCNE | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 69.72 | 53.20 |
| Support Level | $25.78 | $7.36 |
| Resistance Level | $26.20 | $7.95 |
| Average True Range (ATR) | 0.63 | 0.34 |
| MACD | 0.21 | 0.00 |
| Stochastic Oscillator | 89.88 | 47.75 |
CNB Financial Corp is providing integrated financial solutions, which create value for both consumers and businesses. These solutions encompass deposit accounts, private banking, real estate, commercial, industrial, residential and consumer loans and lines of credit, credit cards, treasury services, online banking, mobile banking, merchant credit card processing, remote deposit and accounts receivable handling. It derives revenue through the operations as a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. The company branch are located in Pennsylvania, Ohio, New York and Virginia.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.